Jonathan Loree

930 posts

Jonathan Loree banner
Jonathan Loree

Jonathan Loree

@jonathanloree

GI Medical Oncologist at BC Cancer, Associate Professor at The University of British Columbia, Senior Investigator at the Canadian Cancer Trials Group (CCTG)

Vancouver, British Columbia انضم Mart 2014
328 يتبع846 المتابعون
Jonathan Loree
Jonathan Loree@jonathanloree·
@aparna1024 Prognostic vs predictive important as well. Stellar looked pretty similar for HR and one of our biggest randomized data sets.
English
0
0
1
43
Aparna Raj Parikh
Aparna Raj Parikh@aparna1024·
Less novel from when we first set out to do this, but we thought it was important to look at our own data not just in terms of ICI response but to put more numbers behind what the median OS is in a non-LM versus LM population to help with understanding of benefit.
Noelia Tarazona@TarazonaNoelia

🚀Happy to share our @MassGenBrigham study led by @aparna1024 .🔆In MSS mCRC, absence of liver mets identifies patients more likely to benefit from ICIs, with longer OS and PFS. 🎯Important implications for patient selection and trial design‼️ aacrjournals.org/cancerrescommu…

English
3
3
22
3.7K
A.n.n.
A.n.n.@fireflyann·
@jonathanloree @BCCancer @bccancerfdn @coloncanada Ill circle back and post in fb groups I think FIT tests every 5 years from 30 to 45 makes financial sense. Fine with FIT at 45 if no family history. Definitely a colonoscopy at 50. But if non-compliance, keep the FITs coming
English
1
0
1
89
Jonathan Loree أُعيد تغريده
CCTG
CCTG@CDNCancerTrials·
Applications are being accepted for the #CCTG 2026-2027 New Investigator Cancer Trials Practicum - a training program that enables the brightest new Canadian oncology researchers to acquire training & experience in clinical trial conduct. How to apply: buff.ly/pVU9ts3
CCTG tweet media
English
0
2
1
244
Jonathan Loree
Jonathan Loree@jonathanloree·
A nice retrospective study looking at chemo doublets in biliary tract cancer. "FOLFOX Versus FOLFIRI as Second‐Line Chemotherapy in Patients With Advanced Biliary Tract Cancers: A Multicenter, Italian Study - Pircher - 2026" onlinelibrary.wiley.com/doi/10.1111/li…
English
0
3
8
659
Ronan Hsieh, MD, MS
Ronan Hsieh, MD, MS@ronanhsieh·
Receiving this confirmation letter on the last day of 2025 is so meaningful to me! I am so excited to join NCI Colon Task Force as an early career investigator under the leadership of @smitha42 @jonathanloree Look forward to the next 3 years of research discussion together. I feel humble and eager to learn more from many experts in the field. Special thanks to SWOG GI leadership for giving me this opportunity. @IbrahimSahinMD1
Ronan Hsieh, MD, MS tweet media
English
5
2
22
1.3K
Jonathan Loree أُعيد تغريده
Eric Topol
Eric Topol@EricTopol·
The "Big Bang" of cancer evolution: for colon cancer, evidence that immune evasion occurs very early nature.com/articles/s4158…
English
1
114
583
99K
Rona Yaeger
Rona Yaeger@RonaYaeger·
We looked at this exact question and found that high TMB after targeted therapy, which is more striking in plasma than in tissue, is not sufficient to engender a response to immunotherapy. Manuscript just out! aacrjournals.org/clincancerres/…
Daisuke Kotani, MD, Ph.D 小谷 大輔@DaisukeKotani

High-TMB after anti-EGFR therapy in MSS CRC @ESMO_Open ✅TMB ≥10 (after vs before anti-EGFR): 33.8% vs 9.7% ✅Higher alterations of MAPK signaling 👉Could high-TMB accompanied by "subclonal" alterations after anti-EGFR therapy be a target for immunotherapy? esmoopen.com/article/S2059-… @OncoAlert @oncodaily

English
2
15
59
22K
Jonathan Loree
Jonathan Loree@jonathanloree·
Impact of Human Epidermal Growth Factor Receptor 2 in Patients With Metastatic Colorectal Cancer Treated With Chemotherapy Plus Bevacizumab or Anti-EGFRs: Exploratory Analysis of Eight Randomized Trials | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JC…
English
0
2
7
446
Jonathan Loree أُعيد تغريده
Scott Kopetz
Scott Kopetz@skopetz·
Exciting science and clinical efficacy in this @MDAndersonNews team science study led by @VanMorrisMD In Cancer Cell. Triple therapy with IO led to durable responses in BRAF V600E MSS colorectal cancer, showing promise. Randomized study ongoing. #crcsm cell.com/cancer-cell/fu…
Scott Kopetz tweet media
English
6
24
100
6.2K
Jonathan Loree أُعيد تغريده
soria
soria@jsoriamd·
Liquid biopsies in #CRC 🩸 Serial MRD monitoring: ✔️Detects recurrence 8–11 months earlier than imaging ✔️Improves sensitivity from 40–50% to 80–90% ✔️Helps monitor ACT response Liquid tumor-agnostic assays are evolving: now integrating ✅Methylation ✅Fragmentomics ✅Mutations annalsofoncology.org/article/S0923-…
soria tweet media
English
0
20
61
4.7K

اكتشف

@OHSUKnight @nanets @AmanChauhanMD @OncoThor @FlavioRochaMD @RobertoFedrigo @aparna1024 @fireflyann